MSL
ESPR icon

Mackay Shields LLC’s Esperion Therapeutics ESPR Stock Holding History

Mackay Shields LLC’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-13,900
Closed -$438K – 1494
2020
Q1 		$438K Buy
+13,900
New +$734K ﹤0.01% 1152

Other funds holding ESPR

Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Mackay Shields LLC's ESPR Position: Q2 2020 in Review

Mackay Shields LLC sold out of Esperion Therapeutics (ESPR) in Q2 2020, closing a stake of 13,900 shares — an estimated $438K sold.

Mackay Shields LLC first reported a position in ESPR in Q1 2020 and held it in 1 quarter. The position peaked at $438K in Q1 2020. 183 funds tracked by Wall St. Rank hold ESPR as of Q2 2020.

  • Mackay Shields LLC reported no remaining Esperion Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Mackay Shields LLC sold 13,900 Esperion Therapeutics shares in Q2 2020, an estimated $438K.
  • Mackay Shields LLC first reported a position in Esperion Therapeutics in Q1 2020 and held it in 1 quarter.
  • Mackay Shields LLC's Esperion Therapeutics position peaked at $438K in Q1 2020.
  • 183 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2020.

Based on Mackay Shields LLC's 13F filing for Q2 2020, filed 31 Jul 2020.